The aim of this work is to compare [Ga]Ga-PSMA-11 and [F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data. For [Ga]Ga-PSMA-11, the radiochemical yield (RCY) using a low starting activity (, average activity of 596.55 ± 37.97 MBq) was of 80.98 ± 0.05%, while using a high one (, average activity of 1436.27 ± 68.68 MBq), the RCY was 71.48 ± 0.04%. Thus, increased starting activities of [Ga]-chloride negatively influenced the RCY. A similar scenario occurred for [F]PSMA-1007. The rate of detection of PCa lesions by Positron Emission Tomography/Computed Tomography (PET/CT) was similar for both radioligands, while their distribution in normal organs significantly differed. Furthermore, similar patterns of biodistribution were found among [F]PSMA-1007, [Ga]Ga-PSMA-11, and [Lu]Lu-PSMA-617, the most used agent for RLT. Moreover, the analysis of economical aspects for each single batch of production corrected for the number of allowed PET/CT examinations suggested major advantages of [F]PSMA-1007 compared with [Ga]Ga-PSMA-11. Data from this study should support the proper choice in the selection of the PSMA PET radioligand to use on the basis of the cases to study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227284 | PMC |
| http://dx.doi.org/10.3390/molecules27123862 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA PET vs. mpMRI for Lymph Node Metastasis of Prostate Cancer: A Systematic Review and Head-to-Head Comparative Meta-analysis.
Acad Radiol
December 2024
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Electronic address:
Article Synopsis
- - The study compares the effectiveness of prostate-specific membrane antigen (PSMA) PET scans and multiparametric MRI (mpMRI) in identifying lymph node metastasis (LNM) in prostate cancer, focusing on existing research up to August 2024.
- - Results from 23 articles involving 3,041 patients reveal that PSMA PET has higher sensitivity (74%) compared to mpMRI (45%) for detecting LNM, while both methods show similar specificity (96% for PSMA PET and 92% for mpMRI).
- - The conclusion indicates that PSMA PET is more effective for initial cancer staging, but no significant difference in specificity exists between the two methods, suggesting the need for further research to refine imaging
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications.
BJR Open
January 2024
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW3 6JB, United Kingdom.
Objectives: To quantify the stage-shift with prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic prostate cancer and explore treatment implications.
Methods: Single-centre, retrospective analysis of patients with newly diagnosed [F]PSMA-1007 or [Ga]Ga-PSMA-11 PET/CT-detected metastatic prostate cancer who had baseline bone scintigraphy between January 2015 and May 2021. Patients were subclassified into oligometastatic and polymetastatic disease utilizing the STAMPEDE2 trial (ISRCTN66357938/NCT06320067) definition.
Intratumoral Distribution of [Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer.
Cancer Biother Radiopharm
November 2024
Department of Clinical Sciences Lund, Section for Oncology, Lund University, Lund, Sweden.
Prostate-specific membrane antigen (PSMA) is a target for diagnostic positron emission tomography (PET)-tracers and radiopharmaceutical therapy (RPT), for example, [Lu]Lu-PSMA-617, in prostate cancer. This autoradiography study investigates [Lu]Lu-PSMA-617 intratumoral distribution over time, compared with PSMA expression, proliferation (Ki67), and [Ga]Ga-PSMA-11, [F]F-PSMA-1007, [F]-fluorodeoxyglucose, and [F]-fluorocholine distribution. Mice with LNCaP, 22Rv1, or PC-3 PIP xenografts got [Lu]Lu-PSMA-617 i.
View Article and Find Full Text PDFCu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
J Nucl Med
September 2024
Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland;
The demand for PET tracers that target prostate-specific membrane antigen (PSMA) continues to increase. Meeting this demand with approved Ga- and F-labeled PSMA tracers is challenging outside of major urban centers. This is because the short physical half-life of these radionuclides makes it necessary to produce them near their sites of usage.
View Article and Find Full Text PDFDiverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
J Nucl Med
August 2024
Department of Health Sciences, University of Genova, Genova, Italy.
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!